Stelfonta: How EBC-46 Conquered Canine Cancer and Changed the Course of Oncology Research
How EBC-46 became Stelfonta® — the first FDA and EMA approved intratumoral cancer treatment — through rigorous canine clinical trials, and what this milestone means for the ongoing Phase I/II human cancer trials.
What Is Stelfonta?
Stelfonta® is the brand name for pharmaceutical-grade tigilanol tiglate injection — the same EBC-46 compound found naturally in Blushwood berry seeds. Developed by QBiotics Group, it was the first drug ever approved for direct intratumoral treatment of non-metastatic canine mast cell tumours (MCTs).[1]
FDA and EMA Approval (2020)
In October 2020, the U.S. Food and Drug Administration approved Stelfonta for veterinary use — a landmark decision based on pivotal trial data demonstrating safety and efficacy.[2]
The European Medicines Agency granted marketing authorisation in the same year, making Stelfonta the only intratumoral anti-cancer drug approved in both the US and EU for any species.[3]
Clinical Trial Results
The pivotal randomised controlled trial (De Ridder et al., 2021) enrolled 123 dogs with WHO Stage 0–2 MCTs.[4] Key outcomes:
- 75% complete response rate at the treated tumour site
- Single injection required in the majority of cases
- Response maintained at 12 weeks follow-up for most complete responders
- Well-tolerated with localised inflammatory reactions being the primary side effect
Mechanism in Canine MCTs
Canine mast cell tumours are accessible, well-defined solid tumours — making them ideal candidates for intratumoral injection. EBC-46/tigilanol tiglate's PKC activation mechanism works identically in canine tumours: rapid vascular disruption, haemorrhagic necrosis, and immune-mediated clearance.[5]
Bridge to Human Trials
The veterinary approval and real-world Stelfonta data have directly informed the human clinical trial programme. The canine safety profile — particularly the favourable local tolerability and absence of systemic toxicity at therapeutic doses — provided critical evidence for human Phase I dose escalation.[6]
This cross-species validation pathway is rare in oncology and represents one of the strongest translational evidence bridges in the EBC-46 research story.
References
- U.S. FDA (2020). FDA Approves First Drug for Direct Treatment of Non-Metastatic Canine MCTs. View source ↗
- U.S. FDA (2020). Stelfonta Approval Details. View source ↗
- European Medicines Agency (2020). Stelfonta EPAR Summary. View source ↗
- De Ridder TR et al. (2021). Randomized controlled trial of tigilanol tiglate for canine MCTs. JVIM. View source ↗
- QBiotics Group. Stelfonta Product Information. View source ↗
- ClinicalTrials.gov. Tigilanol tiglate human trials. View source ↗
